Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system

Area of Science:

• Oncology
• Pharmacology
• Bioconjugation Chemistry

Background:

• The EphA2 receptor is frequently overexpressed in various solid tumors, making it a promising target for cancer drug development.
• Targeted delivery systems aim to enhance therapeutic efficacy and reduce systemic toxicity of chemotherapeutics.
• Previous work established EphA2-targeting peptides conjugated with paclitaxel as a potential therapeutic strategy.

Purpose of the Study:

• To investigate the chemical factors influencing the stability and degradation of EphA2-targeting peptide-drug conjugates in plasma.
• To design and synthesize modified peptide-drug conjugates with enhanced stability and anti-cancer activity.
• To evaluate the in vivo efficacy of these novel conjugates in a preclinical cancer model.

Main Methods:

• Synthesis of modified peptide-drug conjugates with alterations in the peptide sequence and linker.
• Assessment of conjugate stability and degradation kinetics in rat plasma.
• Evaluation of anti-tumor efficacy in a prostate cancer xenograft mouse model.

Main Results:

• Modified peptide-drug conjugates exhibited significantly increased stability in plasma compared to unmodified versions.
• The optimized conjugates demonstrated a marked reduction in tumor size in the prostate cancer xenograft model.
• Paclitaxel alone treatment showed less efficacy compared to the targeted peptide-drug conjugates.

Conclusions:

• Chemical modifications to the peptide and linker are critical for enhancing the stability and efficacy of EphA2-targeting peptide-drug conjugates.
• These findings support the hypothesis that peptide-drug conjugates targeting EphA2 offer a viable strategy for selective delivery of cytotoxic drugs to cancer cells.
• The developed agents represent a promising advancement in targeted cancer therapy with potential for improved clinical outcomes.